Bausch & Lomb Corp

Bausch + Lomb reported Q2 2026 revenues of $1.39 billion, an increase from $1.28 billion in Q2 2025. The company significantly reduced its net loss, reporting $(14) million for the quarter, compared to $(62) million in the prior year period. For the six months ended June 30, 2026, revenues reached $2.64 billion, and net cash provided by operating activities increased substantially to $185 million. The company continues to evaluate the separation from Bausch Health Companies Inc.

Bausch + Lomb Corporation announced strong second-quarter 2026 financial results, with total revenue increasing 9% to $1.394 billion. The company significantly improved its GAAP net loss to $14 million and reported Adjusted EBITDA of $241 million. Reflecting this performance, Bausch + Lomb raised its full-year 2026 revenue and Adjusted EBITDA guidance. The company also shared positive topline results from a pivotal clinical study for its enVista Beyond™ investigational IOL.

Bausch & Lomb Corp reported Q1 2026 revenues of $1.24 billion, an increase from $1.14 billion in Q1 2025. The company significantly reduced its net loss to $(70) million, or $(0.20) per share, compared to a net loss of $(211) million, or $(0.60) per share, in the prior year period. Operating income improved to $33 million from an operating loss of $(83) million year-over-year, and cash flow from operations turned positive.

Bausch + Lomb Corp. reported a significant improvement in its Q1 2026 financial performance, with total revenues increasing 9.4% to $1,244 million and net loss attributable to the company substantially reduced to $(71) million from $(212) million year-over-year. Operating income turned positive at $33 million, up from a loss of $(83) million in the prior year period. The company also noted the ongoing evaluation by Bausch Health Companies Inc. regarding the separation of Bausch + Lomb, which may include monetization, sale, or distribution of BHC's ownership interest.

Bausch & Lomb Corp reported a strong first quarter for 2026, with revenues increasing by 9.4% to $1.24 billion. The company significantly improved its operating performance, moving from an operating loss of $(83) million in Q1 2025 to an operating income of $33 million in Q1 2026. Net loss attributable to Bausch + Lomb Corporation was substantially reduced to $(71) million, a 66.5% improvement from the prior year's $(212) million loss. The company also generated $32 million in cash from operating activities, compared to using $(25) million in the same period last year, while BHC continues to evaluate the separation of Bausch + Lomb.

Bausch + Lomb Corporation announced strong first-quarter 2026 financial results, with revenue increasing 9% to $1.244 billion. The company significantly reduced its GAAP net loss to $71 million from $212 million in the prior year, driven by revenue growth and operating efficiencies. Based on this performance and a positive outlook, Bausch + Lomb raised its full-year 2026 revenue and Adjusted EBITDA guidance. Growth was notably strong in Pharmaceuticals, led by MIEBO and XIIDRA, and across its dry eye portfolio and premium intraocular lenses.